Editorial: Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ameri hossein

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF CURRENT OPHTHALMOLOGY Year:2018 | Volume:30 | Issue:1 Page(s): 1-2

Download Full-Text

View:

116

Download:

Cites:

Information Journal Paper

Title

Editorial: Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation

Author(s)

ameri hossein | Issue Writer Certificate

Keywords

Not Registered.

Abstract

The approval of voretigene neparvovec-rzyl by the US Food and Drug Administration (FDA), in December 2017, marked the beginning of a new era in medicine in which many inherited diseases will be essentially corrected by gene therapy. Voretigene neparvovec-rzyl, with the trade name of Luxturna, is the first gene therapy for an inherited disease. It is intended for the treatment of RPE65 mutation-associated retinal dystrophy, making it the second commercially available treatment for inherited retinal disease (IRD) after retinal prostheses (Argus II and Alpha IMS) which were commercialized a few years earlier. Unlike retinal prostheses, voretigene neparvovec-rzyl modifies the course of the disease.

Cites

No record.

References

No record.

Cite

APA: Copy

ameri, hossein. (2018). Editorial: Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. JOURNAL OF CURRENT OPHTHALMOLOGY, 30(1), 1-2. SID. https://sid.ir/paper/758352/en

Vancouver: Copy

ameri hossein. Editorial: Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. JOURNAL OF CURRENT OPHTHALMOLOGY[Internet]. 2018;30(1):1-2. Available from: https://sid.ir/paper/758352/en

IEEE: Copy

hossein ameri, “Editorial: Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation,” JOURNAL OF CURRENT OPHTHALMOLOGY, vol. 30, no. 1, pp. 1–2, 2018, [Online]. Available: https://sid.ir/paper/758352/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops